📋 Key Information Summary
- Diabetic nephropathy (DN) is the leading cause of end-stage renal failure (ESRF) in Australia, accounting for approximately 30–40% of incident dialysis patients.
- DN progresses through five stages: hyperfiltration → silent/microalbuminuria → macroalbuminuria → nephrotic-range proteinuria → ESRF.
- Annual screening with urine albumin-to-creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR) is mandatory from diagnosis in type 2 diabetes and from 5 years post-diagnosis in type 1 diabetes.
- Glycaemic target HbA1c ≤53 mmol/mol (7.0%) reduces microvascular complications; individualise targets in advanced CKD to avoid hypoglycaemia.
- ACE inhibitors (e.g. perindopril, ramipril) or ARBs (e.g. irbesartan, telmisartan) are first-line renoprotective agents — titrate to maximum tolerated dose.
- SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) provide independent renoprotection and reduce CKD progression by 30–40%; initiate if eGFR ≥20 mL/min/1.73 m².
- Finerenone (Kerendia®), a non-steroidal mineralocorticoid receptor antagonist, further reduces kidney and cardiovascular events in DN with persistent albuminuria — requires close potassium monitoring.
- Blood pressure target ≤130/80 mmHg (≤125/75 if ACR >30 mg/mmol) — use combination therapy as needed.
- Lipid management with high-intensity statin (e.g. atorvastatin 40–80 mg) is recommended for all patients with DN and CKD stages 3–5.
- Refer to nephrology if eGFR <30 mL/min/1.73 m², rapid eGFR decline (>5 mL/min/year), refractory hyperkalaemia, or diagnostic uncertainty.
- Aboriginal and Torres Strait Islander peoples experience DN at 3–4× the rate of non-Indigenous Australians with earlier onset and faster progression.
- Smoking cessation, weight optimisation (BMI <30), dietary sodium restriction (<6 g NaCl/day), and regular exercise are essential lifestyle interventions.
- Avoid nephrotoxins — minimise NSAID use, adjust metformin dose when eGFR <45, discontinue metformin if eGFR <15.
Introduction & Australian Epidemiology
Diabetic nephropathy (DN) is a chronic microvascular complication of diabetes mellitus characterised by progressive albuminuria, systemic hypertension, and a relentless decline in glomerular filtration rate (GFR). It is the single leading cause of end-stage renal failure (ESRF) requiring renal replacement therapy (RRT) in Australia and other developed nations.
In Australia, approximately 1.3 million people live with diabetes (primarily type 2), and DN accounts for roughly 30–40% of all incident patients commencing dialysis or kidney transplantation each year. The Australian Institute of Health and Welfare (AIHW) reports that CKD attributable to diabetes has increased steadily over the past two decades, reflecting rising type 2 diabetes prevalence, improved survival in other CKD aetiologies, and increasing recognition of early-stage disease.
DN carries significant cardiovascular morbidity — patients with albuminuria have a 2- to 4-fold increased risk of myocardial infarction, stroke, and cardiovascular death compared with diabetic patients without nephropathy. The economic burden is substantial, with dialysis alone costing approximately ,000–0,000 AUD per patient per year.
Landmark trials — RENAAL, IDNT, ADVANCE, EMPA-KIDNEY, DAPA-CKD, and FIDELIO/FIGARO — have established a multi-targeted approach to DN management, combining glycaemic optimisation, RAAS blockade, SGLT2 inhibition, non-steroidal MRA therapy, and aggressive cardiovascular risk modification. This guideline synthesises current evidence for Australian primary care and specialist practice.
Pathophysiology & Stages (Microalbuminuria to ESRF)
DN arises from the cumulative effects of chronic hyperglycaemia on the glomerular microvasculature, tubulointerstitium, and systemic vasculature. The pathogenesis is multifactorial and involves haemodynamic, metabolic, inflammatory, and fibrotic pathways.
Key Pathogenic Mechanisms
- Glomerular hyperfiltration: Hyperglycaemia induces afferent arteriolar vasodilation and efferent arteriolar constriction (mediated by angiotensin II), raising intraglomerular pressure and GFR. This causes mechanical stress on podocytes and the glomerular basement membrane (GBM).
- Advanced glycation end-products (AGEs): Non-enzymatic glycation of proteins activates the RAGE receptor, promoting inflammation, oxidative stress, and mesangial matrix expansion.
- Polyol and hexosamine pathways: Excess glucose flux generates sorbitol (via aldose reductase) and glucosamine metabolites, contributing to osmotic stress and altered gene expression.
- Podocyte injury: Loss of nephrin and podocin expression leads to foot process effacement and protein leak across the slit diaphragm.
- Tubulointerstitial fibrosis: Progressive tubular atrophy, interstitial inflammation, and fibrosis correlate more closely with declining GFR than glomerular changes alone.
- RAAS activation: Local and systemic RAAS over-activation perpetuates glomerular hypertension, fibrosis, and sodium retention.
Stages of Diabetic Nephropathy
| Stage | Description | ACR (mg/mmol) | eGFR (mL/min/1.73 m²) | Duration to Progression |
|---|---|---|---|---|
| 1 — Hyperfiltration | Enlarged kidneys, elevated GFR, normal albumin excretion | <2.5 (♂) / <3.5 (♀) | >120 (often) | Years |
| 2 — Silent stage | GBM thickening, mesangial expansion; normal ACR and GFR | Normal | Normal | Variable |
| 3 — Microalbuminuria | Incipient nephropathy; earliest clinical detection possible | 2.5–30 (♂) / 3.5–30 (♀) | Normal–mildly reduced | 5–15 years to macro |
| 4 — Macroalbuminuria | Overt nephropathy; progressive GFR decline | >30 | Declining (often 30–60) | 5–10 years to ESRF |
| 5 — ESRF | End-stage renal failure; dialysis or transplant required | Variable (may fall as GFR drops) | <15 | — |
Clinical pearl: Not all diabetic patients with reduced eGFR have DN. Consider non-diabetic causes of CKD (e.g. renovascular disease, obstructive nephropathy, glomerulonephritis) if there is no retinopathy, rapid onset proteinuria, active urine sediment, or atypical clinical trajectory.
Clinical Features & Screening
Clinical Features by Stage
Early DN is clinically silent — the only detectable abnormality is elevated urinary albumin. Symptoms develop insidiously as nephropathy progresses.
Early
Microalbuminuria
Asymptomatic. Elevated ACR on screening. Possible nocturia. Blood pressure may begin to rise. Diabetic retinopathy often coexists.
Setting: Primary care monitoring
Moderate
Macroalbuminuria / Nephrotic
Oedema (peripheral, periorbital). Hypertension (often difficult to control). Frothy urine. Progressive GFR decline. Dyslipidaemia. Anaemia may emerge.
Setting: Nephrology co-management
Severe
ESRF (CKD Stage 5)
Uraemic symptoms (nausea, fatigue, pruritus, encephalopathy). Severe oedema and fluid overload. Refractory hyperkalaemia. Cardiovascular disease. Bone-mineral disorder.
Setting: Dialysis planning / transplant workup
Screening Recommendations (Australian Guidelines)
- Type 2 diabetes: Screen at diagnosis and at least annually thereafter (RACGP / Diabetes Australia).
- Type 1 diabetes: Screen from 5 years after diagnosis and at least annually.
- Screening test: Spot urine albumin-to-creatinine ratio (ACR) — preferred over 24-hour urine collection.
- Confirmatory testing: Persistently elevated ACR on 2 of 3 samples over ≥3 months (exclude transient causes: UTI, acute illness, exercise, menstruation, haematuria).
- eGFR: Calculate using CKD-EPI 2021 equation (creatinine-based, without race coefficient) at each screening visit.
MBS item codes for CKD screening: Urine ACR (MBS item 10088 — urine albumin, quantitative). eGFR is calculated from serum creatinine (MBS item 66521). Both are covered under Medicare as clinically relevant pathology.
Investigations (eGFR, ACR, Biopsy Rarely)
Investigations in DN serve to detect early disease, stage CKD, exclude alternative diagnoses, and monitor progression.
Core Investigations
Essential
Urine Albumin-to-Creatinine Ratio (ACR)
Spot urine sample. MBS item 10088. Normal: <2.5 mg/mmol (♂), <3.5 mg/mmol (♀). Microalbuminuria: 2.5–30 (♂) / 3.5–30 (♀). Macroalbuminuria: >30 mg/mmol.
Essential
eGFR (CKD-EPI 2021)
Calculated from serum creatinine (MBS item 66521). Classify CKD stage: G1 ≥90, G2 60–89, G3a 45–59, G3b 30–44, G4 15–29, G5 <15 mL/min/1.73 m².
Available
Serum Creatinine & Electrolytes
Monitor potassium (critical if on ACEi/ARB/finerenone), bicarbonate, phosphate, calcium. MBS item 66521.
Available
HbA1c
Glycaemic control assessment. Target ≤53 mmol/mol (7.0%) in most; individualise for advanced CKD. Note: may underestimate true glycaemia in ESRF / anaemia / haemoglobin variants.
Available
Lipid Profile
Fasting or non-fasting lipid panel. MBS item 66811. Guide statin therapy.
Available
Full Blood Examination
Anaemia of CKD (normocytic) typically emerges when eGFR <45. MBS item 65070.
Available
Diabetic Retinopathy Screening
Fundoscopy or retinal photography. Presence of retinopathy supports DN diagnosis; absence should prompt consideration of non-diabetic CKD causes.
Specialist
Renal Biopsy
Rarely required — reserved for atypical presentations: absence of retinopathy, rapid nephrotic syndrome onset, active urine sediment (dysmorphic RBCs, casts), unexplained AKI. Performed by nephrologist in a procedural suite.
Available
Renal Ultrasound
May show enlarged, hyperechoic kidneys in early DN; small kidneys in late-stage. Also excludes obstruction and renovascular disease.
CKD Staging (KDIGO Heat Map)
| eGFR Stage | A1 (Normal–mild ↑) | A2 (Moderately ↑) | A3 (Severely ↑) |
|---|---|---|---|
| G1 ≥90 | Green | Yellow | Orange |
| G2 60–89 | Green | Yellow | Orange |
| G3a 45–59 | Yellow | Orange | Red |
| G3b 30–44 | Orange | Red | Red |
| G4 15–29 | Red | Red | Red |
| G5 <15 | Red | Red | Red |
Management (Glycaemic Control, ACEi/ARB, SGLT2i, Finerenone)
Management of DN requires a multi-pronged approach addressing glycaemia, blood pressure, albuminuria, cardiovascular risk, and lifestyle factors simultaneously. Each intervention has additive benefit.
1. Glycaemic Control
Intensive glycaemic control slows the onset and progression of microalbuminuria and retinopathy (UKPDS, DCCT/EDIC, ADVANCE). The benefits on established macroalbuminuria are more modest.
Hypoglycaemia risk in CKD: Insulin and sulfonylurea clearance is reduced in advanced CKD. Metformin accumulation risk when eGFR <45. Always reassess medication doses with declining eGFR.
Metformin
Diabex® · Diaformin® · Glucophage® · Biguanide
Adult dose
500 mg PO BD–TDS; max 2 g/day (immediate release) or 2 g/day (XR)
Renal adjustment
Max 1 g/day if eGFR 30–45. Cease if eGFR <30 (avoid if <15). Hold 48 h before iodinated contrast.
PBS status
✔ PBS General Benefit
Insulin (various)
Humalog® · NovoRapid® · Lantus® · Levemir®
Adult dose
Individualised; reduce basal by 10–20% when eGFR 10–50; reduce by 25–50% if eGFR <10
Paediatric dose
Weight-based; specialist endocrinology input for paediatric DN
PBS status
✔ PBS General Benefit
Linagliptin
Trajenta® · DPP-4 inhibitor
Adult dose
5 mg PO daily — no renal dose adjustment required
Renal adjustment
None needed; hepatic/biliary excretion. Preferred DPP-4i in CKD.
PBS status
✔ PBS General Benefit
2. RAAS Blockade — ACE Inhibitors & ARBs
ACEi and ARBs reduce intraglomerular pressure, lower proteinuria, slow GFR decline, and reduce cardiovascular events. They are the cornerstone of renoprotective therapy in DN.
Contraindication: Do NOT combine ACEi + ARB (dual RAAS blockade) — increases risk of hyperkalaemia, AKI, and hypotension without additional benefit (ONTARGET, VA NEPHRON-D).
Perindopril
Coversyl® · ACE inhibitor
Adult dose
4–8 mg PO daily; start 2–4 mg if elderly or volume-depleted
Renal adjustment
Start at 2 mg if eGFR <60; titrate cautiously. Monitor K⁺ and creatinine at 1–2 weeks after initiation/dose change.
PBS status
✔ PBS General Benefit
Irbesartan
Karvea® · Avapro® · ARB
Adult dose
150–300 mg PO daily
Renal adjustment
No specific dose reduction; use cautiously in advanced CKD. Monitor K⁺.
PBS status
✔ PBS General Benefit
3. SGLT2 Inhibitors
SGLT2 inhibitors have emerged as a transformative therapy for DN, providing renoprotection independent of and additive to glycaemic control. The EMPA-KIDNEY, DAPA-CKD, and CREDENCE trials demonstrated 30–40% reductions in composite kidney endpoints.
Dapagliflozin
Forxiga® · SGLT2 inhibitor
Adult dose
10 mg PO daily — can initiate if eGFR ≥20
Key evidence
DAPA-CKD: 39% reduction in composite kidney endpoint. Benefit sustained regardless of diabetes status.
Renal adjustment
Initiate if eGFR ≥20. If started above 20, may continue down to eGFR ~15. Once ceased for CKD, do not restart for glycaemic benefit alone at low eGFR.
PBS status
✔ PBS Restricted Benefit
Empagliflozin
Jardiance® · SGLT2 inhibitor
Adult dose
10 mg PO daily
Key evidence
EMPA-KIDNEY: 28% reduction in kidney disease progression or CV death.
Renal adjustment
Initiate if eGFR ≥20. Continue if tolerated at lower eGFR.
PBS status
✔ PBS General Benefit (T2DM with CVD risk)
Canagliflozin
Invokana® · SGLT2 inhibitor
Adult dose
100 mg PO daily (max 300 mg if eGFR ≥60)
Key evidence
CREDENCE: 30% reduction in composite kidney endpoint in T2DM with DN.
Renal adjustment
100 mg if eGFR 30–60. Do not initiate if eGFR <30. Discontinue if eGFR persistently <30.
PBS status
✔ PBS Restricted Benefit
SGLT2 inhibitor initiation: Expect an initial 10–15% dip in eGFR (haemodynamic, reversible) — this is NOT a reason to stop. Cease only if eGFR drops >30% sustained, or develops AKI. Monitor for volume depletion, genital mycotic infections, euglycaemic DKA (rare in type 2).
4. Finerenone — Non-Steroidal MRA
Finerenone is a selective non-steroidal mineralocorticoid receptor antagonist that reduces inflammation and fibrosis in the kidney and heart with a lower risk of gynaecomastia and hyperkalaemia compared with spironolactone.
Finerenone
Kerendia® · Non-steroidal MRA
Adult dose
10 mg PO daily initially; if K⁺ ≤4.8 mmol/L after 4 weeks, increase to 20 mg daily
Key evidence
FIDELIO-DKD: 18% reduction in kidney composite. FIGARO-DKD: 13% reduction in CV composite. FIDELITY pooled: significant benefit in both kidney and CV endpoints.
Indication
T2DM with CKD (eGFR ≥25) and persistent albuminuria (ACR ≥30) despite maximised RAAS blockade.
Renal adjustment
Do not initiate if eGFR <25. Monitor K⁺ at 1 week, 4 weeks, then every 4 weeks during titration.
PBS status
✘ Not PBS-listed (as of 2024) — Private/RPBS
Hyperkalaemia monitoring with finerenone: Do not initiate if serum K⁺ >5.0 mmol/L. Recheck at 1 week and 4 weeks. If K⁺ rises >5.5, reduce dose or withhold and recheck. Avoid concurrent potassium supplements, potassium-sparing diuretics, or high-dose trimethoprim.
5. Blood Pressure Management
Hypertension accelerates DN progression. Tight blood pressure control reduces albuminuria and slows GFR decline.
- Target: ≤130/80 mmHg (general DN); ≤125/75 mmHg if ACR >30 mg/mmol (per KDIGO and Australian guidelines).
- First-line: ACEi or ARB (renoprotective beyond BP lowering).
- Second-line add-on: Amlodipine (calcium channel blocker) or indapamide (thiazide-like diuretic).
- Loop diuretic: Furosemide preferred over thiazides if eGFR <30 mL/min.
- Sodium restriction: <6 g NaCl/day (≈2.3 g sodium) — reduces proteinuria and enhances ACEi efficacy.
6. Lipid Management
Cardiovascular disease is the leading cause of death in DN. All patients with DN and CKD stages 3–5 should receive lipid-lowering therapy.
Atorvastatin
Lipitor® · Statin (high-intensity)
Adult dose
40–80 mg PO nocte
Renal adjustment
No dose adjustment required in CKD
PBS status
✔ PBS General Benefit
7. Antiplatelet Therapy
Low-dose aspirin (75–100 mg daily) is recommended for secondary prevention in patients with established CVD. Primary prevention should be individualised (bleeding vs. cardiovascular risk).
8. Smoking Cessation
Smoking doubles the risk of DN progression and ESRF. All patients should be offered pharmacotherapy (varenicline, NRT) and behavioural support. Quitline: 13 78 48.
Monitoring
Regular monitoring is essential to detect progression, titrate medications, and manage complications.
| Parameter | Frequency | Notes |
|---|---|---|
| ACR + eGFR | Every 6–12 months (stable); every 3 months if declining | Confirm persistent albuminuria with repeat testing |
| Serum potassium | 1–2 weeks after ACEi/ARB initiation or dose change; every 3–6 months thereafter | More frequently if on finerenone (1 wk, 4 wk, then monthly) |
| Serum creatinine | With each eGFR check | Expect 10–20% rise after ACEi/ARB start — acceptable if <30% and stabilises |
| HbA1c | Every 3–6 months | May be unreliable in ESRF; use fructosamine or CGM data if available |
| Blood pressure | Each visit; consider ABPM if white-coat suspected | Home BP monitoring encouraged |
| Lipids | Annually (or 6–8 weeks after statin initiation) | Non-fasting acceptable |
| FBE, iron studies | Every 6 months if CKD stage 3b+ | Anaemia of CKD — consider EPO if Hb <100 g/L |
| Calcium, phosphate, PTH | Annually from CKD 3b; more often CKD 4–5 | CKD-mineral bone disorder management |
| Retinal screening | Every 1–2 years | Supports DN diagnosis; concurrent retinopathy common |
| Foot examination | Annually (more if risk factors) | Peripheral neuropathy + PAD screening |
When to Refer to Nephrology
- eGFR <30 mL/min/1.73 m² (CKD stage 4)
- Rapid eGFR decline: >5 mL/min/year sustained
- Refractory hyperkalaemia (K⁺ >5.5 despite intervention)
- Resistant hypertension (≥4 agents at maximally tolerated doses)
- Nephrotic syndrome without typical diabetic pattern
- Suspected non-diabetic kidney disease
- RRT planning — AV fistula creation should occur 6–12 months before anticipated dialysis
Special Populations
Pregnancy
ACEi / ARB: Contraindicated — teratogenic (renal agenesis, oligohydramnios). Cease immediately pre-conception or at pregnancy confirmation. Switch to labetalol, methyldopa, or nifedipine for BP control.
SGLT2 inhibitors: Contraindicated in pregnancy and breastfeeding. Cease pre-conception.
Finerenone: Contraindicated — no safety data in pregnancy.
Statins: Contraindicated in pregnancy — cease pre-conception.
Glycaemia: Insulin is the glucose-lowering agent of choice in pregnancy. Tight targets (fasting <5.0, 1-hr post-prandial <7.4 mmol/L) to reduce congenital anomaly risk. Multidisciplinary care with endocrinology, obstetrics, and nephrology.
Paediatrics
Screening: Type 1 diabetes: screen from age 11 or 5 years post-diagnosis (whichever is earlier), annually. Type 2 diabetes: screen at diagnosis and annually.
ACEi: Enalapril 0.08–0.6 mg/kg/day PO — first-line for microalbuminuria in paediatric DN. PBS Authority may be required.
SGLT2i: Limited paediatric data; not routinely recommended outside clinical trials.
Glycaemia: Insulin pump therapy and CGM preferred in paediatric type 1. Endocrinology-led care.
Elderly (≥75 years)
Glycaemic targets: Relaxed to HbA1c ≤64 mmol/mol (8.0%) if frailty, limited life expectancy, or hypoglycaemia risk. Avoid sulfonylureas (gliclazide MR preferred if required).
ACEi/ARB: Start low, titrate slowly. Monitor for postural hypotension, AKI, hyperkalaemia.
SGLT2i: Caution for volume depletion — ensure adequate hydration. Assess fall risk.
Finerenone: Higher hyperkalaemia risk in elderly — more frequent K⁺ monitoring.
Advanced CKD (eGFR <30)
Metformin: Cease if eGFR <30. Lactic acidosis risk.
SGLT2i: May continue if already initiated above eGFR 20. Do not start de novo below 20.
Insulin: Reduce dose by 25–50% in CKD stage 5. Monitor for hypoglycaemia closely.
ESA therapy: Consider erythropoietin-stimulating agent if Hb <100 g/L and iron replete. Refer to nephrology.
RRT planning: Discuss dialysis modality and transplant eligibility early. AV fistula creation at eGFR 15–20.
Hepatic Impairment
Metformin: Avoid in severe hepatic impairment (Child-Pugh C) — lactic acidosis risk.
Linagliptin: Preferred DPP-4 inhibitor as hepatically cleared; no renal adjustment needed.
Statins: Use cautiously; avoid if active liver disease. Monitor LFTs.
Immunocompromised
Infections: DN patients on immunosuppression (e.g. post-transplant) face compounded infection risk. Vaccinate appropriately (pneumococcal, influenza, COVID-19, hepatitis B).
Drug interactions: Calcineurin inhibitors (cyclosporin, tacrolimus) potentiate nephrotoxicity and hyperkalaemia — coordinate with transplant team.
Aboriginal and Torres Strait Islander Health Considerations
Aboriginal and Torres Strait Islander Health
📚 References
- 1. KDIGO 2024 Clinical Practice Guideline for Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024;105(4S):S117–S314.
- 2. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (CREDENCE). N Engl J Med. 2019;380(24):2295–2306.
- 3. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD). N Engl J Med. 2020;383(15):1436–1446.
- 4. The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117–127.
- 5. Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes (FIDELIO-DKD). N Engl J Med. 2020;383(23):2219–2229.
- 6. Filippatos G, Anker SD, Agarwal R, et al. Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes (FIGARO-DKD). Circulation. 2021;143(6):540–552.
- 7. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy (RENAAL). N Engl J Med. 2001;345(12):861–869.
- 8. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes (IDNT). N Engl J Med. 2001;345(12):851–860.
- 9. Australian Institute of Health and Welfare. Chronic kidney disease: Australian facts. AIHW, Canberra. 2023.
- 10. RACGP / Diabetes Australia. General practice management of type 2 diabetes 2016–2018 (updated 2020). The Royal Australian College of General Practitioners, Melbourne.
- 11. Kidney Health Australia. Chronic Kidney Disease (CKD) Management in Primary Care. 4th edition. Melbourne: Kidney Health Australia; 2020.
- 12. Heart Foundation of Australia. Position statement: Management of hypertension in adults with type 2 diabetes. 2023.
- 13. RHDAustralia (ARF/RHD writing group). The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease. 3rd edition. Menzies School of Health Research, Darwin.
- 14. National Aboriginal Community Controlled Health Organisation (NACCHO). Aboriginal and Torres Strait Islander chronic disease resources. NACCHO, Canberra.